Pfizer Inc. has expanded on the long lead it had with Xeljanz (tofacitinib) over competing Janus kinase (JAK) inhibitors by engineering more selective next-generation drugs in this class, including abrocitinib, for which the company presented the first detailed Phase III atopic dermatitis (AD) data on 12 October in a late-breakers session at the European Academy of Dermatology and Venereology (EADV) meeting in Madrid.
Positive top-line results already have been reported for abrocitinib, a selective inhibitor of JAK1, in two out of three Phase III clinical trials meant to support a US Food and Drug Administration filing in the second half of 2020 for the treatment of moderate-to-severe AD
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?